a rapid and efficient method for generation of iPSC
The discovery of induced pluripotent stem cells (iPSC) has provided a major advance in biomedical research as they are able to offer meaningful models to investigate human diseases and biology. A growing number of research laborat...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
CELLNAIVETY
Deciphering the Molecular Foundations and Functional Compete...
2M€
Cerrado
EBiSC2
EBiSC2 A sustainable European Bank for induced pluripotent...
9M€
Cerrado
EBISC
European Bank for induced pluripotent Stem Cells
34M€
Cerrado
EBISC
European Bank for induced pluripotent Stem Cells
34M€
Cerrado
SAF2015-72617-EXP
REPROGRAMACION Y REGENERACION TISULAR A PARTIR DE MICROVESIC...
48K€
Cerrado
RYC-2009-05080
Reprogramación de telómeros en células madre pluripotenciale...
192K€
Cerrado
Información proyecto EASY-IPS
Duración del proyecto: 27 meses
Fecha Inicio: 2018-11-12
Fecha Fin: 2021-02-28
Líder del proyecto
FONDAZIONE TELETHON ETS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
150K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The discovery of induced pluripotent stem cells (iPSC) has provided a major advance in biomedical research as they are able to offer meaningful models to investigate human diseases and biology. A growing number of research laboratory are using iPSC for studying a wide variety of human diseases. iPSC have also tremendous potential for regenerative medicine because they can be virtually differentiated in any type of cell. Through the support of the ERC grant IEMTx, we built-up an in-house protocol for generation of iPSC from patients’ cell lines that is efficient and has an extremely low cost compared to other available methods with the highest clinical safety. Therefore, we can offer a superior system to produce iPSC based on a simpler, more efficient, highly reproducible, cost effective and customizable process. Moreover, HDAd have potential also for cell trans-differentiation that is the reprogramming of one somatic cell type into another cell type without passing through the pluripotent state. In summary, the goal of this proposal is to pave the way towards commercialization of our novel products for generating iPSC and trans-differentiated cell lines based on HDAd vectors as non-integrating, high-cloning capacity, inexpensive and easy to use vectors. We believe this method will become a relevant opportunity for biomedical research and might find applications in regenerative medicine as well.